Cerebrospinal fluid calcium, parathyroid hormone, and monoamine and purine metabolites and the blood-brain barrier function in primary hyperparathyroidism.
Psychiatric disturbances are common in primary hyperparathyroidism (HPT), but their pathogenesis is essentially unknown. This study deals with cerebrospinal fluid (CSF) calcium homeostasis and its connection with parathyroid hormone (PTH), blood-brain barrier (BBB) function, and central monoamine and purine metabolites in patients with primary HPT. In 22 patients with primary HPT (serum calcium 2.85 +/- 0.21 mmol/l), the CSF concentrations of total and ionized calcium were higher (1.21 +/- 0.08 mmol/l, p less than 0.01, and 1.09 +/- 0.05 mmol/l, p less than 0.001, respectively) than in 11 normocalcemic reference subjects. The values correlated with serum calcium concentration (p less than 0.001) and CSF/serum albumin ratio, a measure of BBB permeability. The latter ratio was elevated in one-third of the patients with HPT, indicating BBB damage. CSF immunoreactive intact PTH was higher in the HPT patients than in the reference group (p less than 0.05), and serum and CSF PTH were positively correlated (p less than 0.05). The CSF levels of the monoamine metabolites 5-hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) were lower, and the level of urate in CSF was higher, in the HPT patients than in the reference subjects, while there were no consistent differences in CSF hypoxanthine or xanthine. CSF 5HIAA correlated inversely with CSF ionized calcium (r = -0.42, p = 0.02). After parathyroid surgery, CSF calcium and urate decreased significantly and CSF monoamine metabolites increased slightly. The decrease in CSF ionized calcium correlated with the alleviation of psychiatric symptoms. The results indicate the importance of increased CSF calcium concentrations in patients with primary HPT and suggest a relation between central calcium regulation and central turnover of monoamines.
Joborn
C
C
Department of Internal Medicine, University Hospital, Uppsala, Sweden.
Hetta
J
J
Niklasson
F
F
Rastad
J
J
Wide
L
L
Agren
H
H
Akerström
G
G
Ljunghall
S
S
D001812:Blood-Brain Barrier / Q000502:physiology*; D002118:Calcium / Q000134:cerebrospinal fluid*; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D006961:Hyperparathyroidism / Q000503:physiopathology* / Q000523:psychology; D019271:Hypoxanthine; D007042:Hypoxanthines / Q000134:cerebrospinal fluid*; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid*; D019965:Neurocognitive Disorders / Q000503:physiopathology* / Q000523:psychology; D010280:Parathyroid Glands / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000134:cerebrospinal fluid*; D012709:Serum Albumin / Q000134:cerebrospinal fluid; D019820:Xanthine; D014970:Xanthines / Q000134:cerebrospinal fluid*
D007042:Hypoxanthines; D010281:Parathyroid Hormone; D012709:Serum Albumin; D014970:Xanthines; D019820:Xanthine; D019271:Hypoxanthine; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D002118:Calcium; D006719:Homovanillic Acid